Based on their presence and known biological role in liver disease we propose that CD44, VEGF-C, LYVE-1, PAI-1, BPI, MPO, TN-C, NPNT, ATX and ADAMTSL4 warrant further evaluation as potential candidate biomarkers of CSPH in cACLD. This evidence concerns the gene ADAMTSL4 and liver disorder.